Cyp2c38 Inhibitors
Cyp2c38 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the Cyp2c38 enzyme, a member of the cytochrome P450 superfamily. The Cyp2c38 enzyme is involved in the oxidative metabolism of a diverse range of substrates, including endogenous compounds such as fatty acids, steroids, and signaling molecules, as well as exogenous substances like drugs and environmental chemicals. As part of the cytochrome P450 family, Cyp2c38 plays a critical role in the detoxification processes by catalyzing the monooxygenation of its substrates. This process typically involves the insertion of an oxygen atom into the substrate molecule, increasing its solubility and facilitating its further metabolism or excretion. The activity of Cyp2c38 is especially significant in tissues such as the liver, where it contributes to the metabolic processing of various substances that the organism encounters.
Inhibitors of Cyp2c38 are typically small molecules that are designed to bind to the enzyme's active site, thereby preventing it from catalyzing the oxidation of its substrates. These inhibitors work by occupying the substrate-binding pocket, blocking the natural substrates from accessing the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The design and development of Cyp2c38 inhibitors require a deep understanding of the enzyme's three-dimensional structure, particularly the regions involved in substrate recognition and catalysis. By inhibiting Cyp2c38, researchers can explore its specific role in various metabolic pathways and gain insights into how the inhibition of this enzyme affects the metabolism of different compounds within the body. The study of Cyp2c38 inhibitors provides valuable insights into the enzyme's substrate specificity, its interaction with other metabolic enzymes, and its overall contribution to maintaining metabolic balance within the organism. This research is crucial for understanding the diverse roles of cytochrome P450 enzymes in the biotransformation of chemical entities and their importance in sustaining cellular and systemic homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole, a potent inhibitor of Cyp2c38, disrupts arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It interferes with the arachidonic acid metabolic process, influencing cellular responses related to diseases such as Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole inhibits Cyp2c38 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses related to arachidonic acid metabolism, potentially affecting diseases such as multiple chemical sensitivity. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
Abiraterone serves as a direct inhibitor of Cyp2c38, influencing arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It impacts cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine acts as a direct inhibitor of Cyp2c38, disrupting arachidonic acid metabolism. By affecting epoxygenase activities, it modulates pathways associated with diseases like invasive aspergillosis and multiple chemical sensitivity. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine inhibits Cyp2c38 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It influences cellular responses related to diseases such as glucose metabolism disease and invasive aspergillosis. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole serves as a direct inhibitor of Cyp2c38, impacting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine acts as a direct inhibitor of Cyp2c38, disrupting arachidonic acid metabolism. By affecting epoxygenase activities, it modulates pathways associated with diseases like invasive aspergillosis and multiple chemical sensitivity. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole inhibits Cyp2c38 directly, disrupting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It influences cellular responses related to diseases such as glucose metabolism disease and invasive aspergillosis. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole serves as a direct inhibitor of Cyp2c38, impacting arachidonic acid 11,12-epoxygenase and 14,15-epoxygenase activities. It modulates cellular responses linked to diseases, including Plasmodium falciparum malaria and eosinophilic esophagitis. | ||||||